A new technique using light signals and AI can accurately predict EGFR mutations in lung cancer — no gene sequencing required. Developed by researchers at the University of Edinburgh and NHS Lothian, the method is faster, cheaper, and preserves precious biopsy tissue. It could help clinicians match patients to targeted treatments far more quickly than current lab approaches.
Researchers at the University of Edinburgh and NHS Lothian have developed a new way to detect EGFR mutations in lung cancer patients — without expensive, time-consuming genetic sequencing. The technique, called fluorescence lifetime imaging microscopy (FLIM), captures natural light signals from untreated tissue samples, which are then analyzed by an AI model to identify mutation patterns with high accuracy.
The method can also distinguish between the two most common EGFR mutation subtypes — a critical distinction for treatment decisions. Because it uses tissue without any staining or processing, the biopsy sample remains intact and available for further analysis, addressing a major bottleneck in diagnostic pathways where tissue availability is often limited.
Key Takeaways:
Why it matters: As expanded lung cancer screening programs detect more early-stage cancers, diagnostic services face growing pressure to deliver fast, accurate results from smaller tissue samples. A non-destructive, AI-assisted scan that rapidly identifies actionable mutations could be a game-changer — especially for health systems with limited access to complex molecular testing.
